IBDEI0IX ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8515,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,8515,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,8516,0)
 ;;=C92.40^^39^401^20
 ;;^UTILITY(U,$J,358.3,8516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8516,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,8516,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,8516,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,8517,0)
 ;;=D56.0^^39^401^21
 ;;^UTILITY(U,$J,358.3,8517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8517,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,8517,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,8517,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,8518,0)
 ;;=D63.1^^39^401^23
 ;;^UTILITY(U,$J,358.3,8518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8518,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,8518,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,8518,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,8519,0)
 ;;=D63.0^^39^401^24
 ;;^UTILITY(U,$J,358.3,8519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8519,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,8519,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,8519,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,8520,0)
 ;;=D63.8^^39^401^22
 ;;^UTILITY(U,$J,358.3,8520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8520,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,8520,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,8520,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,8521,0)
 ;;=C22.3^^39^401^27
 ;;^UTILITY(U,$J,358.3,8521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8521,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,8521,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,8521,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,8522,0)
 ;;=D61.9^^39^401^28
 ;;^UTILITY(U,$J,358.3,8522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8522,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,8522,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,8522,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,8523,0)
 ;;=D56.1^^39^401^34
 ;;^UTILITY(U,$J,358.3,8523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8523,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,8523,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,8523,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,8524,0)
 ;;=C83.79^^39^401^36
 ;;^UTILITY(U,$J,358.3,8524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8524,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8524,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,8524,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,8525,0)
 ;;=C83.70^^39^401^37
 ;;^UTILITY(U,$J,358.3,8525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8525,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,8525,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,8525,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,8526,0)
 ;;=D09.0^^39^401^44
 ;;^UTILITY(U,$J,358.3,8526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8526,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,8526,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,8526,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,8527,0)
 ;;=D06.9^^39^401^45
 ;;^UTILITY(U,$J,358.3,8527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8527,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,8527,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,8527,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,8528,0)
 ;;=D06.0^^39^401^47
 ;;^UTILITY(U,$J,358.3,8528,1,0)
 ;;=^358.31IA^4^2
